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INTRODUCTION
Bioequivalence	 tests	 are	 a	 way	 to	 evaluate	
the	 efficacy	 of	 a	 drug.	 In	 the	 bioequivalence	
study	 a	 number	 of	 closely	 related	 parameters	
are	evaluated	(Ognean	et al.,	2008).	Among	these	
parameters	 are	 the	 time	 to	 peak	 concentration	
(Tmax),	 representing	 the	necessary	 time	needed	
for	 the	 active	 substance	 to	 reach	 the	 maximum	








The	 study	 aims	 to	 evaluate	 and	 compare	
the	 necessary	 time	 to	 attain	 the	maximum	 drug	
concentration	 in	 the	 blood	 (T
max
)	 and	 to	 assess	
the	 half-time	 (T
1/2




included,	 clinically	healthy,	 coming	 from	rural	or	
urban	 environment.	 The	 cats	 were	 admitted	 for	
testing	according	to	a	series	of	inclusion/exclusion	
criteria.	Each	 subject	was	 submitted	 to	an	 initial	
screening,	consisting	of	clinical,	hematological	and	
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drug	 administered	 (test	 or	 reference)	 however	




),	 there	 are	 observed	 fluctuations	 of	 the	
individual	values	and	also	variations	of	the	mean	
results	 obtained	 (Fig.1).	 Thus,	 for	 the	 TEST	
product,	 a	mean	 value	 of	 1250.58	 ±	 607.53	 ng/
mL	 was	 obtained,	 with	 a	 maximum	 of	 2423.21	
ng/mL	and	a	minimum	of	356.96	ng/mL.	For	the	
REFERENCE	 product,	 the	 mean	 recorded	 value	
was	 925.78	 ±	 515.39	 ng/mL,	 with	 a	 maximum	
value	of	1823.89	ng/mL	and	a	minimum	value	of	
184.68	ng/mL.
For	 the	 products	 half-life,	 as	 it	 can	 be	
noticed	 in	 Fig.	 2,	 only	 minor	 fluctuations	 of	 the	
individual	 results	 were	 recorded.	 This	 aspect	 is	
more	noticeable	 for	 the	 test	product,	were	 small	











Since	 the	 two	 products	 had	 a	 different	 con-
centration	 of	 praziquantel,	 the	 individual	 re-
sults	 obtained	 indicate	 that	 there	 are	 variable	
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    Fig.2.	Individual	results	for	T
1/2
